Your browser doesn't support javascript.
loading
Oral Ondansetron versus Domperidone for Acute Gastroenteritis Associated Vomiting in Young Children.
Hanif, Hamza; Jaffry, Hassam; Jamshed, Fatima; Amreek, Fnu; Kumar, Naresh; Hussain, Wajid; Rizwan, Amber.
Afiliação
  • Hanif H; Internal Medicine, Jinnah Sindh Medical University, Karachi, PAK.
  • Jaffry H; Internal Medicine, Jinnah Sindh Medical University, Karachi, PAK.
  • Jamshed F; Pediatrics, Jinnah Sindh Medical University, Karachi, PAK.
  • Amreek F; S. Arthur Localio Laboratory, New York University School of Medicine, New York, USA.
  • Kumar N; Medicine, Dow University of Health Sciences (DUHS), Karachi, PAK.
  • Hussain W; Pediatric Medicine, National Institute of Child Health, Karachi, PAK.
  • Rizwan A; Family Medicine, Dr. Ruth Pfau Hospital, Karachi, PAK.
Cureus ; 11(9): e5639, 2019 Sep 12.
Article em En | MEDLINE | ID: mdl-31700742
ABSTRACT
Introduction The management of vomiting and antiemetic therapy in young children with acute gastroenteritis (AGE) has not been standardized by any management guidelines. Antiemetic drugs including promethazine, prochlorperazine, metoclopramide, ondansetron, and domperidone are readily used in the emergency departments (EDs). The aim of this study was to compare the efficacy of ondansetron with domperidone in cessation of vomiting in pediatric AGE. Methods This open-label, two-arm trial was conducted in a pediatric ED in Pakistan. Children of age 1 to 60 months presenting with acute vomiting and no or mild-to-moderate dehydration associated with AGE were randomized into two groups. Group A children received ondansetron suspension orally at a dose of 0.15 mg/kg body weight. Group B received domperidone suspension orally at a dose of 0.5 mg/kg body weight. The primary outcome was the number of children in each group who did not have any episode of vomiting 24 hours posttreatment. The data were entered and analyzed using Statistical Package for the Social Sciences (SPSS) for Windows version 20.0 (IBM Corp., Armonk, NY). Results At 6 hours, 87% of children in the ondansetron group improved and their vomiting episodes ceased as compared to 81% of children in the domperidone group. The differences were statistically insignificant (p>0.05). At 24 hours, 95% in the ondansetron group had improved and only 85% in the domperidone group. The results were statistically significant favoring the end results of the ondansetron (p=0.01). Conclusions This study concluded that ondansetron is more efficacious than domperidone in cessation of vomiting associated with AGE and no or mild-to-moderate dehydration in children of age three months to five years.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Guideline / Risk_factors_studies Idioma: En Revista: Cureus Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Guideline / Risk_factors_studies Idioma: En Revista: Cureus Ano de publicação: 2019 Tipo de documento: Article